Skip to content
Injectable Index

Juvéderm

Juvéderm is a family name, not one interchangeable hyaluronic acid gel. In the United States, six named XC fillers span different HA concentrations, labeled anatomies, and placement contexts. SKINVIVE by JUVÉDERM uses the family name but has its own skin-smoothness and neck-line indications, so it is kept visible without treating it as merely another contour filler.

This page uses current US FDA records and US labeling as its regulatory anchor. The FDA P050047 record 🔗 covers the earlier Ultra lineage; P110033 and its supplements 🔗 cover VOLUMA XC and the later products. A shared PMA lineage does not make the formulations or indications equivalent.

US formulation and presentation matrix

Section titled “US formulation and presentation matrix”

All products below are sterile, ready-to-use, cross-linked HA gels produced using Streptococcus species and formulated in physiologic buffer. Each contains 0.3% w/w lidocaine. The concentration and presentation belong to the exact product.

Exact US productHA concentrationCrosslinking description in the cited US recordCurrent labeled presentation summarized
JUVÉDERM Ultra XC24 mg/mLCross-linked bacterial-source HAIndividual treatment syringe; supplied with 30-G needles
JUVÉDERM Ultra Plus XC24 mg/mLCross-linked bacterial-source HAIndividual treatment syringe; supplied with 27-G needles
JUVÉDERM VOLUMA XC20 mg/mLBDDE-cross-linked HA, primarily cross-linked with some lightly cross-linked and uncross-linked HATwo prefilled 1 mL syringes per box
JUVÉDERM VOLLURE XC17.5 mg/mLCross-linked bacterial-source HATwo prefilled 1 mL syringes per box; current DFU supplies 30-G needles
JUVÉDERM VOLBELLA XC15 mg/mLBDDE-cross-linked HATwo 1 mL prefilled syringes per box, each tray packaged with two sterile needles
JUVÉDERM VOLUX XC25 mg/mLBDDE-cross-linked HATwo 1 mL prefilled syringes per box; supplied with 27-G needles
SKINVIVE by JUVÉDERM12 mg/mLBDDE-cross-linked HAIndividual treatment syringe; supplied with 32-G needles

Sources: current US Ultra XC DFU 🔗, Ultra Plus XC DFU 🔗, VOLUMA XC temple-indication SSED 🔗, VOLLURE XC SSED 🔗, VOLBELLA XC infraorbital SSED 🔗, VOLUX XC SSED 🔗, and the June 2026 SKINVIVE DFU 🔗.

XC identifies a lidocaine-containing US product name in this family, but it does not establish that two XC products share concentration, gel architecture, syringe, supplied tool, or indication. Package configurations can also change; verify the current carton and DFU rather than treating this table as inventory guidance.

US indications and placement remain product-specific

Section titled “US indications and placement remain product-specific”
Exact US productFDA-labeled objective and anatomyPlacement stated in the current approval context
Ultra XCModerate-to-severe facial wrinkles and folds, such as nasolabial folds; also lip and perioral augmentation in adults over 21Mid-to-deep dermis for wrinkles and folds; the lip indication is stated separately
Ultra Plus XCModerate-to-severe facial wrinkles and folds, such as nasolabial foldsMid-to-deep dermis
VOLLURE XCModerate-to-severe facial wrinkles and folds, such as nasolabial folds, in adults over 21Mid-to-deep dermis
VOLBELLA XCLip augmentation and correction of perioral rhytids; improvement of infraorbital hollowing, in adults over 21The infraorbital labeling describes subcutaneous and/or supraperiosteal placement at the orbital rim; do not transfer that plane to its lip indication
VOLUMA XCCheek augmentation for age-related midface volume deficit; chin augmentation to improve chin profile; temple augmentation for moderate-to-severe temple hollowing, in adults over 21Deep subcutaneous and/or supraperiosteal for cheek and chin; supraperiosteal for temple
VOLUX XCImprovement of jawline definition in adults over 21 with moderate-to-severe loss of definitionSubcutaneous and/or supraperiosteal
SKINVIVE by JUVÉDERMImprove cheek skin smoothness; reduce neck lines to improve neck appearance, in adults over 21Intradermal for cheeks; intradermal and/or subdermal for neck

The six-filler indications are consolidated on the current US Juvéderm professional page 🔗. Key expansions are documented separately in FDA records: VOLUMA XC chin, P110033/S047 🔗, VOLUMA XC temple, P110033/S070 🔗, VOLBELLA XC infraorbital hollowing, P110033/S053 🔗, and VOLUX XC jawline, P110033/S065 🔗.

The table is a label map, not an anatomy-based recommendation. A familiar off-label use, a trainer preference, or a sibling product’s placement wording does not expand an exact variant’s US indication.

Hylacross and Vycross are attributed technology terms

Section titled “Hylacross and Vycross are attributed technology terms”

Allergan Aesthetics presents Hylacross and Vycross as proprietary technology headings within the US filler portfolio. Its professional science page describes Hylacross using high-molecular-weight HA at 24 mg/mL and high cohesivity, and describes Vycross as a range using high-molecular-weight HA across 15–25 mg/mL concentrations (Juvéderm professional science page 🔗).

Those names help track a manufacturer’s formulation lineage. They do not independently disclose:

  • crosslinking degree or every manufacturing step
  • residual BDDE or molecular-weight distribution
  • a rheology value under a specified method
  • equivalence between products within the named technology
  • a preferred anatomy, safety ranking, or guaranteed duration

Ultra XC and Ultra Plus XC share the 24 mg/mL concentration but remain distinct regulated products. The VOLUMA, VOLLURE, VOLBELLA, and VOLUX records show concentrations from 15 to 25 mg/mL and different indications. These facts illustrate why neither a technology name nor mg/mL can substitute for the exact label. See Formulation and Gel Architecture and Rheology and Physical Properties before interpreting laboratory comparisons.

SKINVIVE is a boundary case with a clear US regulatory identity

Section titled “SKINVIVE is a boundary case with a clear US regulatory identity”

SKINVIVE is not non-cross-linked mesotherapy material. The current FDA DFU identifies it as a 12 mg/mL BDDE-cross-linked HA gel implant with 0.3% lidocaine. FDA approved it on May 11, 2023 for intradermal injection to improve cheek skin smoothness, then on June 11, 2026 expanded the indication to intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance (P110033/S059 🔗; P110033/S099 🔗).

That regulatory identity matters in both directions:

  • its skin-quality objective should not be rewritten as conventional focal volume correction
  • the marketing category skin booster should not replace its exact US device identity, formulation, placement, or indication
  • its inclusion under the Juvéderm name does not make every hydration-oriented injectable a Juvéderm-like filler
  • the cheek indication and the newer neck indication have different labeled placement wording

Company and regulatory relationships

Section titled “Company and regulatory relationships”
RoleSupported US relationship
FDA PMA applicantAllergan, at the Irvine address shown in P050047 and P110033 records
US aesthetic commercial contextAllergan Aesthetics
Parent-company contextAllergan Aesthetics is an AbbVie company
Trademark contextCurrent US DFUs identify JUVÉDERM and the variant marks as trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates
Production contextCurrent US DFUs state Made in France; AbbVie describes its French facility as producing and shipping Juvéderm syringes
Exact legal manufacturerVerify from the current regional label or establishment record; Made in France alone is not a legal-entity name

The relationship between Allergan Aesthetics and AbbVie is supported by AbbVie’s Allergan Aesthetics company description 🔗. AbbVie’s 2022 French manufacturing milestone announcement 🔗 supports the broad production context but should not be used to assign a legal manufacturer to every regional SKU.

Regional names are not aliases by default

Section titled “Regional names are not aliases by default”

The US records establish the products and presentations above only for the United States. Other markets use names including with Lidocaine, and some products have historically been associated with different regional names. For example, the FDA VOLLURE SSED notes marketing under JUVÉDERM VOLIFT with Lidocaine outside the US; that history does not by itself prove that every current VOLIFT and VOLLURE presentation is identical.

Before mapping a non-US product to a US variant, verify the exact local IFU, concentration, lidocaine, syringe volume, supplied tool, indication, approval holder, and document date. Do not infer equivalence from the VOL- stem, similar packaging, a shared technology term, or an older FDA marketing-history paragraph.

Safety and hyaluronidase interpretation

Section titled “Safety and hyaluronidase interpretation”

The current US labels contraindicate these products in patients with severe allergy histories described in the label and in patients with allergy to Gram-positive bacterial proteins or lidocaine. Commonly reported injection-site effects across the six-filler collection include redness, swelling, pain, tenderness, firmness, lumps or bumps, bruising, discoloration, and itching. The labels also warn that intravascular injection can cause embolization, vascular occlusion, ischemia or infarction, with rare serious outcomes including skin necrosis, vision impairment or blindness, and stroke (US Juvéderm indications and safety information 🔗; SKINVIVE 2026 DFU 🔗).

Hyaluronidase can enzymatically degrade HA, and Juvéderm labels discuss it in management contexts. That does not make reversible a complete product property or promise immediate, uniform, complication-free removal. Response depends on the exact gel, enzyme preparation, exposure, amount, timing, anatomy, and clinical objective. Elective aesthetic correction, suspected vascular compromise, infection, and inflammatory nodules require different assessment and escalation pathways.

Section titled “Related reference pages”